---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-097226"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2026-08-14T20:30:44+00:00"
generated_at: "2026-08-14T20:36:26.655433+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma Q2 2026 net loss $3.0M, no revenue; cash $5.0M, runway into Q1 2027

## Summary
- Q2 2026 net loss $3.0M ($0.16/share) vs $0.9M loss in Q2 2025; no revenue vs $2.7M prior.
- Cash $5.0M at June 30, 2026 vs $3.8M at Dec 31, 2025; expects runway into Q1 2027, may need more financing.
- MHRA resubmission for tivoxavir marboxil expected Q3 2026; FDA clinical hold still unresolved, response planned by end 2026.
- April 2026 financing delivered $10M upfront, potential $50M via warrants; shareholders approved Series B and C on July 8, 2026.
- Six-month net loss $10.2M vs net income $20.6M in 2025 (due to $26.7M warrant gain).

## SEC filing metadata
- accession: 0001104659-26-097226
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2026-08-14T20:30:44+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465926097226/0001104659-26-097226-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465926097226/tm2623190d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-097226
- JSON: https://secwatch.observer/filing/0001104659-26-097226.json
- Plain text: https://secwatch.observer/filing/0001104659-26-097226.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.